Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Jul 26, 2014; 6(7): 562-576
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.562
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.562
Ref. | Clinical setting | Number of patients | CMR parameters | End-points(mean follow-up) | Results |
Assomoul et al[26], 2006 | NIDCM | 101 | Midwall fibrosis (LGE) | All-cause death and hospitalization (follow-up 658 ± 355 d) | Independent association with death and hospitalization |
Wu et al[27], 2008 | NIDCM and LVEF ≤ 35% | 65 | Presence and extent of LGE | Composite end-point (hospitalization for heart failure, appropriate ICD firing, cardiac death) (Follow-up median 24 mo) | Presence of LGE was associated with a greater risk of primary outcome |
Iles et al[28], 2011 | IDCM/NIDCM before ICD implantation | 103 | Regional fibrosis with LGE | Arrhythmic events and appropriate ICD therapy (follow-up 573 d) | LGE was associated with arrhythmic events and appropriate ICD therapy during follow-up |
Lehrke et al[29], 2011 | NIDCM | 184 | Presence of LGE | Composite end-point (hospitalization for decompensated heart failure, cardiac death, cardioverter defibrillator discharge) (follow-up 31 mo) | Presence of LGE was associated with composite endpoint |
Gao et al[30], 2012 | IDCM/NIDCM | 124 | Presence and quantification of LGE | Primary composite outcome: occurrence of appropriate ICD therapy, SCA, SCD (follow-up 632 ± 262 d) | Myocardial scar quantification by LGE-CMR predicts arrhythmic events in patients being evaluated for ICD eligibility |
Neilan et al[31], 2013 | NIDCM | 162 | Presence and quantification of LGE | Major adverse cardiac events (cardiovascular death and appropriate ICD therapy) (follow-up: 29 ± 18 mo) | Presence of LGE was a strong predictor of major cardiac events |
Li et al[32], 2013 | NIDCM | 293 | Presence and extent of LGE | All-cause mortality (follow-up: 3.2 yr) | Presence of LGE is an independent predictor of increased all-cause mortality Diffuse LGE is associated with higher mortality |
Gulati et al[33], 2013 | NIDCM | 472 | Presence and extent of midwall fibrosis | Primary end-point: all cause mortality Secondary end-point: cardiovascular mortality or cardiac transplantation Arrhythmic and HF secondary end-points (follow-up 5.3 yr) | Midwall fibrosis assessed with LGE-CMR provided independent prognostic information and improved risk stratification beyond LVEF for all-cause mortality and SCD |
- Citation: Iacoviello M, Monitillo F. Non-invasive evaluation of arrhythmic risk in dilated cardiomyopathy: From imaging to electrocardiographic measures. World J Cardiol 2014; 6(7): 562-576
- URL: https://www.wjgnet.com/1949-8462/full/v6/i7/562.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i7.562